HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.
Joura
Elmar A
EA
Department of Gynecology and Obstetrics, Medical University of Vienna, Vienna, Austria. elmar.joura@meduniwien.ac.at
Kjaer
Susanne K
SK
Wheeler
Cosette M
CM
Sigurdsson
Kristján
K
Iversen
Ole-Erik
OE
Hernandez-Avila
Mauricio
M
Perez
Gonzalo
G
Brown
Darron R
DR
Koutsky
Laura A
LA
Tay
Eng Hseon
EH
García
Patricia
P
Ault
Kevin A
KA
Garland
Suzanne M
SM
Leodolter
Sepp
S
Olsson
Sven-Eric
SE
Tang
Grace W K
GW
Ferris
Daron G
DG
Paavonen
Jorma
J
Lehtinen
Matti
M
Steben
Marc
M
Bosch
Xavier
X
Dillner
Joakim
J
Kurman
Robert J
RJ
Majewski
Slawomir
S
Muñoz
Nubia
N
Myers
Evan R
ER
Villa
Luisa L
LL
Taddeo
Frank J
FJ
Roberts
Christine
C
Tadesse
Amha
A
Bryan
Janine
J
Lupinacci
Lisa C
LC
Giacoletti
Katherine E D
KE
Lu
Shuang
S
Vuocolo
Scott
S
Hesley
Teresa M
TM
Haupt
Richard M
RM
Barr
Eliav
E
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis* / Q000276:immunology*; D003218:Condylomata Acuminata / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D052163:Human papillomavirus 6 / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014621:Vagina / Q000473:pathology; D014626:Vaginal Smears; D014844:Vulva / Q000473:pathology; D055815:Young Adult
D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines